.Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA09_Atomoxetine.Atomoxetine .Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA09_Atomoxetine.Atomoxetine| name: | Atomoxetine | |
| ATC code: | N06BA09 | route: | oral |
| compartments: | 1 | |
| dosage: | 40 | mg |
| volume of distribution: | 0.85 | L |
| clearance: | 22 | L/h |
| other parameters in model implementation | ||
Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It is a non-stimulant medication and is approved by regulatory agencies for the treatment of ADHD.
Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.
Sauer, JM, et al., & Witcher, JW (2005). Clinical pharmacokinetics of atomoxetine. Clinical pharmacokinetics 44(6) 571–590. DOI:10.2165/00003088-200544060-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15910008
Chalon, SA, et al., & Horsmans, Y (2003). Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clinical pharmacology and therapeutics 73(3) 178–191. DOI:10.1067/mcp.2003.25 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12621383
De Hondt, L, et al., & Tommelein, E (2024). Quantification of ADHD medication in biological fluids of pregnant and breastfeeding women with liquid chromatography: a comprehensive review. Frontiers in public health 12 1437328–None. DOI:10.3389/fpubh.2024.1437328 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39171321